Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia.
Cancer Res
; 64(2): 672-7, 2004 Jan 15.
Article
in En
| MEDLINE
| ID: mdl-14744784
ABSTRACT
Imatinib mesylate (IM) binds to the BCR-ABL protein, inhibiting its kinase activity and effectively controlling diseases driven by this kinase. IM resistance has been associated with kinase mutations or increased BCR-ABL expression. However, disease progression may be mediated by other mechanisms that render tumor cells independent of BCR-ABL. To demonstrate this potential, IM-resistant cells were found in chronic myelogenous leukemia patients with continuous BCR-ABL gene expression but undetectable BCR-ABL protein expression. These cells were unresponsive to IM and acquired BCR-ABL-independent signaling characteristics. IM resistance in some patients may be mediated through loss of kinase target dependence.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Piperazines
/
Pyrimidines
/
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/
Fusion Proteins, bcr-abl
/
Drug Resistance, Neoplasm
Limits:
Humans
Language:
En
Journal:
Cancer Res
Year:
2004
Document type:
Article
Affiliation country:
United States